Organisation paid for research Program year 2025 Source: CMS Open Payments

WakeMed

Neither a doctor nor a teaching hospital

Research payments

$228,385

32 payments

Through program year 2025, WakeMed is reported as receiving $228,385 in research payments, across 32 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$69,188	10
2024	Research	$78,007	5
2023	Research	$9,954	2
2022	Research	$12,196	1
2021	Research	$14,288	2
2020	Research	$2,984	3
2019	Research	$41,769	9

Breakdown

Who paid Research payments · program years 2019–2025

Solventum Corporation $144,507 14 payments
Amgen Inc. $30,538 7 payments
Janssen Research & Development, LLC $26,246 5 payments
Cardiovascular Systems Inc. $8,288 1 payment
KCI USA, Inc $7,500 1 payment
Medical Device Business Services, Inc. $6,000 1 payment
Abbott Laboratories $2,688 1 payment
Daiichi Sankyo Inc. $1,500 1 payment
CVRx, Inc. $1,119 1 payment

Studies the money was for Research payments · program years 2019–2025

A Prospective, Single-arm, Multi-center, Open Label Trial Evaluating the Continuous Application of Prevena Therapy for up to 14 days $116,509 8 payments
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure (METEORIC-HF) $29,613 6 payments
A Prospective, Single-arm,Multi-center, Open Label Trial Evaluating the Continuous Application of Prevena Therapy for up to 14 days $22,898 5 payments
A Randomized Multi Center Double Blind Parallel Group Placebo Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents =10 to <18 Years With Type 2 Diabetes Mellitus $14,650 2 payments
A Prospective, Single-arm, Multi-center, Open Label Trial Evaluating the Continuous Application of PrevenaTherapy for up to 14 days $12,600 2 payments
A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (=10 to <18 Years) With Type 2 Diabetes Mellitus $11,596 3 payments
Affirm PCI $8,288 1 payment
WaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF Mediated Stroke 2 $6,000 1 payment
Eclipse $2,688 1 payment
Wel-A-U307 $1,500 1 payment

What the money was spent on Research payments · program years 2019–2025

Patient care $8,288 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.